Industry
Biotechnology
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 10:26 am
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 10:49 am
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:22 pm
Portfolio Pulse from Benzinga Insights
June 11, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 07, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
June 04, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
May 29, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 5:42 am
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:13 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.